Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review

References

• BRIDGE: Bridging Gaps, Expanding Outreach For Metastatic Breast Cancer PatientsBreast200918527327519616435
   PubMed Web of Science ®Google Scholar
• JangGLeeSAhnJClinical features and course of brain metastases in triple-negative breast cancer: Comparison with HER2+ and other typeJ Clin Oncol20092715s Suppl
   Google Scholar
• ScruggsKPradhanSMMfalilaCDifferential timing and patterns of recurrence among breast cancer subtypesJ Clin Oncol20092715s Suppl
   Google Scholar
• KoblerJThe reluctant surgeon A biography of John HunterGarden City, New YorkDoubleday & Company, Inc.1960
   Google Scholar
• HertigAAngiogenesis in the early human chorion and in the primary placenta of the macaque monkeyContr Embryol Carnegie Inst1935253781
   Google Scholar
• AlgireGHC HWLegallaisFYParkHDVascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplantsJ Natl Cancer Inst194567385
   Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• BremHFolkmanJInhibition of tumor angiogenesis mediated by cartilageJ Exp Med197514124274391113064
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun198916128518582735925
   PubMed Web of Science ®Google Scholar
• SengerDRGalliSJDvorakAMTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience198321945879839856823562
   PubMed Web of Science ®Google Scholar
• CulyCBevacizumab: antiangiogenic cancer therapyDrugs Today (Barc)2005411233615753967
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• DvorakHFVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyJ Clin Oncol200220214368438012409337
   PubMed Web of Science ®Google Scholar
• SaifMWMerrittJRobbinsJPhase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinomaClin Colorectal Cancer20066322923417026795
   PubMed Web of Science ®Google Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200422112184219115169807
   PubMed Web of Science ®Google Scholar
• TyagiPBevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trialClin Lung Cancer20056527627815845177
   PubMedGoogle Scholar
• AghajanianCThe role of bevacizumab in ovarian cancer – an evolving storyGynecol Oncol2006102213113316846774
   PubMed Web of Science ®Google Scholar
• MonkBJChoiDCPugmireGBurgerRAActivity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecol Oncol200596390290515721449
   PubMed Web of Science ®Google Scholar
• GrayRBhattacharyaSBowdenCIndependent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancerJ Clin Oncol200927304966497219720913
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKDuicPRoyceCStroudIPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• HanahanDFolkmanJPatterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell19968633533648756718
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor as a target for anticancer therapyOncologist20049Suppl 121015178810
   PubMed Web of Science ®Google Scholar
• AchenMGJeltschMKukkEVascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)Proc Natl Acad Sci U S A19989525485539435229
   PubMed Web of Science ®Google Scholar
• WeidnerNFolkmanJPozzaFTumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinomaJ Natl Cancer Inst19928424187518871281237
   PubMedGoogle Scholar
• WeidnerNSempleJPWelchWRFolkmanJTumor angiogenesis and metastasis – correlation in invasive breast carcinomaN Engl J Med19913241181701519
   PubMed Web of Science ®Google Scholar
• ShweikiDItinANeufeldGGitay-GorenHKeshetEPatterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesisJ Clin Invest1993915223522437683699
   PubMed Web of Science ®Google Scholar
• RakJYuJLKlementGKerbelRSOncogenes and angiogenesis: signaling three-dimensional tumor growthJ Investig Dermatol Symp Proc2000512433
   Google Scholar
• LaughnerETaghaviPChilesKMahonPCSemenzaGLHER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expressionMol Cell Biol200121123995400411359907
   PubMed Web of Science ®Google Scholar
• HerbstRSTherapeutic options to target angiogenesis in human malignanciesExpert Opin Emerg Drugs200611463565017064223
   PubMedGoogle Scholar
• LinYSNguyenCMendozaJLPreclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorJ Pharmacol Exp Ther199928813713789862791
   PubMed Web of Science ®Google Scholar
• MargolinKGordonMSHolmgrenEPhase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety dataJ Clin Oncol200119385185611157039
   PubMed Web of Science ®Google Scholar
• HseiVDeguzmanGGNixonAGaudreaultJComplexation of VEGF with bevaczumab decreases VEGF clearance in ratsPharm Res200219111753175612458683
   PubMed Web of Science ®Google Scholar
• CobleighMALangmuirVKSledgeGWA phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancerSemin Oncol2003305 Suppl 1611712414613032
   PubMed Web of Science ®Google Scholar
• MillerKDChapLIHolmesFARandomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerJ Clin Oncol200523479279915681523
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• MilesDChanARomieuGRandomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADOJ Clin Oncol200826520 Suppl abstr LBA1011
   Google Scholar
• MilesDChanARomieuGFinal overall survival (OS) results from the randomized, double-blind, placebo-controlled, phase 3 AVADO study of bevacizumab (B) plus docetaxel (D) complared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC)Cancer Research2010
   Google Scholar
• O’ShaughnessyJABrufskyAMRiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancerClin Breast Cancer20088437037318757267
   PubMed Web of Science ®Google Scholar
• RobertNDierasVGlaspyJRIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)Journal of Clinical Oncology20092715S (May 20 Suppl), ASCO Annual Meeting Proceedings (Post-Meeting Edition)
   Google Scholar
• DicklerMNRugoHSEberleCAA phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerClin Cancer Res200814237878788319047117
   PubMed Web of Science ®Google Scholar
• Bagheri-YarmandRVadlamudiRKWangRAMendelsohnJKumarRVascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesisJ Biol Chem200027550394513945710967114
   PubMed Web of Science ®Google Scholar
• ArriagaYBecerraCRAdverse effects of bevacizumab and their management in solid tumorsSupport Cancer Ther20063424725018632501
   PubMedGoogle Scholar
• KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol2003211606512506171
   PubMed Web of Science ®Google Scholar
• PandeALombardoJSpangenthalEJavleMHypertension secondary to anti-angiogenic therapy: experience with bevacizumabAnticancer Res2007275B3465347017972502
   PubMed Web of Science ®Google Scholar
• GordonCRRojavinYPatelMA review on bevacizumab and surgical wound healing: an important warning to all surgeonsAnn Plast Surg200962670770919461291
   PubMed Web of Science ®Google Scholar
• SaifMWElfikyASalemRRGastrointestinal perforation due to bevacizumab in colorectal cancerAnn Surg Oncol20071461860186917356952
   PubMed Web of Science ®Google Scholar
• SaifMWMehraRIncidence and management of bevacizumab-related toxicities in colorectal cancerExpert Opin Drug Saf20065455356616774493
   PubMed Web of Science ®Google Scholar
• ChengXMoroneyJWLevenbackCFFuSJaishuenAKavanaghJJWhat is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?J Chemother200921556657219933049
   PubMed Web of Science ®Google Scholar
• BesseBLasserreSFComptonPHuangJAugustusSRohrUPBevacizumab safety in patients with central nervous system metastasesClin Cancer Res16126927820028762
   PubMed Web of Science ®Google Scholar
• MarinellaMAMarkertRJReversible posterior leukoencephalopathy syndrome associated with anticancer drugsIntern Med J2008
   Web of Science ®Google Scholar
• VaughnCZhangLSchiffDReversible posterior leukoencephalopathy syndrome in cancerCurr Oncol Rep2008101869118366965
   PubMed Web of Science ®Google Scholar
• AyllonJLaunay-VacherVMedioniJCrosCSpanoJPOudardSOsteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?Ann Oncol200920360060119188135
   PubMed Web of Science ®Google Scholar
• ChristodoulouCPervenaAKlouvasGCombination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates aloneOncology200976320921119212145
   PubMed Web of Science ®Google Scholar
• RyanPTungNMIsakoffSJNeoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacyJ Clin Oncol20092715s Suppl
   Google Scholar
• GolshanMGarberJGelmanRSurgical complications and the use of neoadjuvant bevacizumabCancer Rese200969Suppl 24496s
   Web of Science ®Google Scholar
• JainRKDudaDGWillettCGBiomarkers of response and resistance to antiangiogenic therapyNat Rev Clin Oncol20096632733819483739
   PubMed Web of Science ®Google Scholar
• InceWLJubbAMHoldenSNAssociation of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabJ Natl Cancer Inst2005971398198915998951
   PubMedGoogle Scholar
• JubbAMHurwitzHIBaiWHolmgrenEBTobinPGuerreroASImpact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancerJ Clin Oncol200624221722716365183
   PubMed Web of Science ®Google Scholar
• SchneiderBPRadovichMMillerKDThe role of vascular endothelial growth factor genetic variability in cancerClin Cancer Res200915175297530219706811
   PubMed Web of Science ®Google Scholar
• Paez-RibesMAllenEHudockJTakedaTAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRSAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
   PubMed Web of Science ®Google Scholar